These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30181817)

  • 21. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
    J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
    Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
    Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.
    Long ZJ; Wang LX; Zheng FM; Chen JJ; Luo Y; Tu XX; Lin DJ; Lu G; Liu Q
    Int J Oncol; 2015; 46(6):2488-96. PubMed ID: 25872528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
    Breccia M; Efficace F; Alimena G
    Cancer Lett; 2011 Jan; 300(2):115-21. PubMed ID: 21074936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigational strategies in chronic myelogenous leukemia.
    Cortes JE; O'Brien SM; Giles F; Alvarez RH; Talpaz M; Kantarjian HM
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):619-39, ix. PubMed ID: 15271396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction: MiR-124 acts as a target for Alzheimer's disease by regulating BACE1.
    An F; Gong G; Wang Y; Bian M; Yu L; Wei C
    Oncotarget; 2018 May; 9(37):24871. PubMed ID: 29873327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
    James AR; Unnikrishnan BS; Priya R; Joseph MM; Manojkumar TK; Raveendran Pillai K; Shiji R; Preethi GU; Kusumakumary P; Sreelekha TT
    Tumour Biol; 2017 Mar; 39(3):1010428317695946. PubMed ID: 28345463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
    Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
    Agarwal S; Milazzo G; Rajapakshe K; Bernardi R; Chen Z; Eveline B; Koster J; Perini G; Coarfa C; Shohet JM
    Oncotarget; 2018 Jul; 9(52):30024. PubMed ID: 30042831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2017; 12(10):e0186528. PubMed ID: 29020096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China.].
    Wang JX; Huang XJ; Wu DP; Hu JD; Liu T; Hu Y; Meng FY; Chen XQ; Hou M; Li Y; Wang SJ; Wang JM; Ren HY; Yu L; Chen FY; Qiu LG; Jiang B; Sun AN; Liu TB; Zhu HL; Guo T; Xu D; Ji CY; Lü XY; Jiao L; Song XM; Huang HH
    Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):721-5. PubMed ID: 20137304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis.
    Arundhathi A; Chuang WH; Chen JK; Wang SE; Shyr YM; Chen JY; Liao WN; Chen HW; Teng YM; Pai CC; Wang CH
    Oncotarget; 2019 Jan; 10(4):558. PubMed ID: 30728905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction: The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.
    Visochek L; Atias D; Spektor I; Castiel A; Golan T; Cohen-Armon M
    Oncotarget; 2020 Feb; 11(5):571-572. PubMed ID: 32082490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
    Rudzki J; Wolf D
    Expert Rev Hematol; 2011 Apr; 4(2):153-9. PubMed ID: 21495925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.
    Alves R; Gonçalves AC; Jorge J; Alves J; Alves da Silva A; Freitas-Tavares P; Nascimento Costa JM; Almeida AM; Sarmento-Ribeiro AB
    Med Oncol; 2019 Feb; 36(3):30. PubMed ID: 30796703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HE; Liu AJ; Wang KL; Shih CM
    PLoS One; 2017; 12(3):e0173828. PubMed ID: 28267803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
    Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
    Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.
    Xiao Y; Jiao C; Lin Y; Chen M; Zhang J; Wang J; Zhang Z
    DNA Cell Biol; 2017 Jan; 36(1):18-25. PubMed ID: 27854515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.